Evidence map›Paper›PMID 36910579›Full record

ArticleJournal of biomolecular techniques : JBT2022

Commercial ChIP-Seq Library Preparation Kits Performed Differently for Different Classes of Protein Targets.

M S Simper, L Della Coletta, S Gaddis, K Lin, C D Mikulec, True Takata, M W Tomida, D Zhang, D G Tang, M R Estecio and 2 more

Abstract read
In one paragraph

Article in Journal of biomolecular techniques : JBT, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. A side-by-side comparison of commercial CUT&RUN kits.Journal of biomolecular techniques : JBT · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

M S SimperDepartment of Epigenetics and Molecular Carcinogenesis The University of Texas MD Anderson Cancer Center Science ParkSmithvilleTexas78957 USA.
L Della ColettaDepartment of Epigenetics and Molecular Carcinogenesis The University of Texas MD Anderson Cancer Center Science ParkSmithvilleTexas78957 USA.
S GaddisDepartment of Epigenetics and Molecular Carcinogenesis The University of Texas MD Anderson Cancer Center Science ParkSmithvilleTexas78957 USA.
K LinDepartment of Epigenetics and Molecular Carcinogenesis The University of Texas MD Anderson Cancer Center Science ParkSmithvilleTexas78957 USA.
C D MikulecDepartment of Epigenetics and Molecular Carcinogenesis The University of Texas MD Anderson Cancer Center Science ParkSmithvilleTexas78957 USA.
True TakataDepartment of Epigenetics and Molecular Carcinogenesis The University of Texas MD Anderson Cancer Center Science ParkSmithvilleTexas78957 USA.
M W TomidaDepartment of Epigenetics and Molecular Carcinogenesis The University of Texas MD Anderson Cancer Center Science ParkSmithvilleTexas78957 USA.
D ZhangDepartment of Epigenetics and Molecular Carcinogenesis The University of Texas MD Anderson Cancer Center Science ParkSmithvilleTexas78957 USA.
D G TangDepartment of Epigenetics and Molecular Carcinogenesis The University of Texas MD Anderson Cancer Center Science ParkSmithvilleTexas78957 USA.
M R EstecioDepartment of Epigenetics and Molecular Carcinogenesis The University of Texas MD Anderson Cancer Center Science ParkSmithvilleTexas78957 USA.
J ShenDepartment of Epigenetics and Molecular Carcinogenesis.
Yue LuDepartment of Epigenetics and Molecular Carcinogenesis The University of Texas MD Anderson Cancer Center Science ParkSmithvilleTexas78957 USA.

Funding

Novel Therapeutic Strategies to Co-Target Undifferentiated Prostate Cancer (PCa) Stem Cells and Bulk PCa CellsR01CA240290 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI Dean G. Tang · 2019 to 2026
$3.1M
NCI NIH HHS R01 CA240290
6 · The paper itself

Abstract

Background: Chromatin immunoprecipitation followed by high-throughput sequencing (ChIP-Seq) is a powerful method commonly used to study global protein-DNA interactions including both transcription factors and histone modifications. We have found that the choice of ChIP-Seq library preparation protocol plays an important role in overall ChIP-Seq data quality. However, very few studies have compared ChIP-Seq libraries prepared by different protocols using multiple targets and a broad range of input DNA levels. Results: In this study, we evaluated the performance of 4 ChIP-Seq library preparation protocols (New England Biolabs [NEB] NEBNext Ultra II, Roche KAPA HyperPrep, Diagenode MicroPlex, and Bioo [now PerkinElmer] NEXTflex) on 3 target proteins, chosen to represent the 3 typical signal enrichment patterns in ChIP-Seq experiments: sharp peaks (H3K4me3), broad domains (H3K27me3), and punctate peaks with a protein binding motif (CTCF). We also tested a broad range of different input DNA levels from 0.10 to 10 ng for H3K4me3 and H3K27me3 experiments. Conclusions: Our results suggest that the NEB protocol may be better for preparing H3K4me3 (and potentially other histone modifications with sharp peak enrichment) libraries; the Bioo protocol may be better for preparing H3K27me3 (and potentially other histone modifications with broad domain enrichment) libraries, and the Diagenode protocol may be better for preparing CTCF (and potentially other transcription factors with well-defined binding motifs) libraries.  For ChIP-Seq experiments using novel targets without a known signal enrichment pattern, the NEB protocol might be the best choice, as it performed well for each of the 3 targets we tested across a wide array of input DNA levels.

Indexed as

Chromatin Immunoprecipitation SequencingHistonesDNAGene LibraryHigh-Throughput Nucleotide SequencingSequence Analysis, DNATranscription FactorsDNAHistonesTranscription FactorsChIP-Seqlibrary preparationnext generation sequencingquality control

Identifiers

PMID36910579
PMCPMC10001930

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.